bioeq GmbH
🇩🇪Germany
A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 3
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Bioeq GmbH
- Target Recruit Count
- 392
- Registration Number
- NCT04595409
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Phase 3
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: FYB203 (Proposed aflibercept biosimilar)
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Bioeq GmbH
- Target Recruit Count
- 434
- Registration Number
- NCT04522167
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Phase 3
Completed
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Biological: ranibizumab
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Bioeq GmbH
- Target Recruit Count
- 712
- Registration Number
- NCT02611778
- Locations
- 🇬🇧
Research Site, Rugby, United Kingdom
🇩🇪University of Bonn, Department of Ophthalmology, Bonn, Germany
© Copyright 2025. All Rights Reserved by MedPath